We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Intravenous Human Immunoglobulins Neutralizes Omicron Subvariants BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/BA.5 for Treatment of Coronavirus Disease 2019.
- Authors
Awasthi, Mayanka; Golding, Hana; Khurana, Surender
- Abstract
Our study demonstrates that neither 2020 convalescent plasma (CP) nor 2019/2020 intravenous immunoglobulin (IVIG) neutralizes Omicron subvariants BA.1 to BA.5. In contrast, 2020 hyperimmune anti–severe acute respiratory syndrome coronavirus 2 IVIG (hCoV-2IG) lots neutralized Omicron variants of concern, similar to results with 2022 CP from BA.1 breakthrough infections. Therefore, high-titer hCoV-2IG and CP could be evaluated for treatment of high-risk individuals infected with circulating Omicron subvariants.
- Subjects
SARS-CoV-2; COVID-19; IMMUNOGLOBULINS; GENETIC variation; INTRAVENOUS immunoglobulins; CONVALESCENT plasma; RESEARCH funding
- Publication
Clinical Infectious Diseases, 2023, Vol 76, Issue 3, pe503
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciac642